Freda C Lewis-Hall
CIK 1437909 · Executive Vice President · last filed 2026-03-25
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
PFE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
130 WAVERLY STREET
CAMBRIDGE, MA 02139
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PYXS | Director | 241,405 | $1.81 | $436.9K | $0 | 6 | 2026-03-25 |
| CDTTW | Director | 39,801 | $0.00 | $135 | $0 | 4 | 2025-08-26 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Director | 4,017,245 | $46.99 | $188.77M | $900.0K | 9 | 2025-07-02 |
| CDT | Director | — | $0.08 | — | $0 | 1 | 2023-12-14 |
| EXACT SCIENCES CORP (EXAS) Delisted | Director | 19,688 | $104.91 | $2.07M | $0 | 5 | 2023-06-12 |
| 1Life Healthcare Inc (ONEM) Delisted | Director | 4,534 | $16.47 | $74.7K | $0 | 3 | 2022-06-06 |
| PFE | Executive Vice President | 468,690 | $29.68 | $13.91M | -$1.10M | 113 | 2019-03-01 |
| THC | Director | 15,314 | $260.06 | $3.98M | $0 | 3 | 2016-05-17 |
| VRTX | EVP, Medicines Development | 53,334 | $517.94 | $27.62M | -$106.3K | 5 | 2009-03-20 |
Recent Filings · Page 13 of 15
150 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2010-10-01 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-09-17 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-09-02 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-09-02 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-08-17 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-08-03 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-07-16 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-07-01 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-06-16 | PFE | Grant (A) | — | $0 | EDGAR |
| 2010-06-01 | PFE | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.